Fragment-Based Drug Discovery of Kinase Inhibitors

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 461-483

  Erlanson, Daniel A ^a  

^a Sunesis Pharmaceuticals Inc   (United States)

Author keywords

B Raf kinase inhibitor using fragment based methods; Cyclin dependent kinase 2 (CDK2) multiple anticancer drug target in clinics; Fragment based drug discovery of kinase inhibitors

Indexed keywords

EID: 84871551462     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch18     Document Type: Chapter

References (81)

1. Abad-Zapatero, C., and Metz, G. (2005). Ligand efficiency indices as guideposts for drug discovery. Drug Discov Today. 10, 464-469.
2. Becattini, B., Culmsee, C., Leone, M., et al. (2006). Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc Natl Acad Sci USA. 103, 12602-12606.
3. Bohacek, R. S., McMartin, C., and Guida, W. C. (1996). The art and practice of structure-based drug design: a molecular modeling perspective. Med Res Rev. 16, 3-50.
4. Bohm, H. J. (1992). The computer program LUDI: a new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des. 6, 61-78.
5. Bramson, H. N., Corona, J., Davis, S. T., et al. (2001). Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J Med Chem. 44, 4339-4358.
6. Burley, S. K. (2008). Discovery and development of selective, orally bioavailable tyrosine kinase inhibitors for targeted treatment of human cancers. In: CHI's Third Annual Drug Discovery Chemistry 2008: Tools, Targets & Therapies, La Jolla, CA.
7. Caldwell, J. J., Davies, T. G., Donald, A., et al. (2008). Identification of 4-(4 -aminopiperidin-1-yl)-7 H-pyrrolo[2, 3-d ]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 51, 2147-2157.
8. Cancilla, M. T., He, M. M., Viswanathan, N., et al. (2008). Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg Med Chem Lett. 18, 3978-3981.
9. Card, G. L., Blasdel, L., England, B. P., et al. (2005). A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol. 23, 201-207.
10. Chen, J., Zhang, Z., Stebbins, J. L., et al. (2007). A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem Biol. 2, 329-336.
11. Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., and Nicosia, S. V. (2005). The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 24, 7482-7492.
12. Congreve, M. S., Davis, D. J., Devine, L., et al. (2003). Detection of ligands from a dynamic combinatorial library by X-ray crystallography. Angew Chem Int Ed Engl. 42, 4479-4482.
13. Congreve, M., Chessari, G., Tisi, D., and Woodhead, A. J. (2008). Recent developments in fragment-based drug discovery. J Med Chem. 51, 3661-3680.
14. Cook, R., Wu, C. C., Kang, Y. J., and Han, J. (2007). The role of the p38 pathway in adaptive immunity. Cell Mol Immunol. 4, 253-259.
15. DeLano, W. L. PyMOL molecular graphics system on World Wide Web. http://pymol.sourceforge.net/.
16. Donald, A., McHardy, T., Rowlands, M. G., et al. (2007). Rapid evolution of 6 -phenylpurine inhibitors of protein kinase B through structure-based design. J Med Chem. 50, 2289-2292.
17. Enkvist, E., Raidaru, G., Vaasa, A., Pehk, T., Lavogina, D., and Uri, A. (2007). Carbocyclic 3 ′-deoxyadenosine-based highly potent bisubstrate-analog inhibitor of basophilic protein kinases. Bioorg Med Chem Lett. 17, 5336-5339.
18. Erlanson, D. A. (2006). Fragment-based lead discovery: a chemical update. Curr Opin Biotechnol. 17, 643-652.
19. Erlanson, D. A. (2007). Fragment-based ligand discovery meets phage display. ACS Chem Biol. 2, 779-782.
20. Erlanson, D., Braisted, A., Raphael, D., et al. (2000). Site-directed ligand discovery. Proc Natl Acad Sci USA. 97, 9367-9372.
21. Erlanson, D. A., Lam, J. W., Wiesmann, C., et al. (2003). In situ assembly of enzyme inhibitors using extended tethering. Nat Biotechnol. 21, 308-314.
22. Erlanson, D. A., McDowell, R. S., and O'Brien, T. (2004a). Fragment-based drug discovery. J Med Chem. 47, 3463-3482.
23. Erlanson, D. A., Wells, J. A., and Braisted, A. C. (2004b). Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 33, 199-223.
24. Fejzo, J., Lepre, C. A., Peng, J. W., et al. (1999). The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Chem Biol. 6, 755-769.
25. Fejzo, J., Lepre, C., and Xie, X. (2003). Application of NMR screening in drug discovery. Curr Top Med Chem. 3, 81-97.
26. Fink, T., Bruggesser, H., and Reymond, J. L. (2005). Virtual exploration of the small -molecule chemical universe below 160 daltons. Angew Chem Int Ed Engl. 44, 1504-1508.
27. Fischer, P. M. (2004). The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle. 3, 742-746.
28. Gassel, M., Breitenlechner, C. B., Ruger, P., et al. (2003). Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). J Mol Biol. 329, 1021-1034.
29. Gill, A. (2004). New lead generation strategies for protein kinase inhibitors-fragment based screening approaches. Mini Rev Med Chem. 4, 301-311.
30. Gill, A., Cleasby, A., and Jhoti, H. (2005a). The discovery of novel protein kinase inhibitors by using fragment-based high-throughput X-ray crystallography. Chembiochem. 6, 506-512.
31. Gill, A. L., Frederickson, M., Cleasby, A., et al. (2005b). Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. J Med Chem. 48, 414-426.
32. Gill, A. L., Verdonk, M., Boyle, R. G., and Taylor, R. (2007). A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti -cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 7, 1408-1422.
33. Hajduk, P. J., and Greer, J. (2007). A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov. 6, 211-219.
34. Hajduk, P. J., Sheppard, G., Nettesheim, D. G., et al. (1997). Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc. 119, 5818-5827.
35. Hann, M. M., and Oprea, T. I. (2004). Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol. 8, 255-263.
36. Hann, M. M., Leach, A. R., and Harper, G. (2001). Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci. 41, 856-864.
37. Hopkins, A. L., Groom, C. R., and Alex, A. (2004). Ligand efficiency: a useful metric for lead selection. Drug Discov Today. 9, 430-431.
38. Hubbard, R. E., Davis, B., Chen, I., and Drysdale, M. J. (2007). The SeeDs approach: integrating fragments into drug discovery. Curr Top Med Chem. 7, 1568-1581.
39. Hunter, T. (2007). Treatment for chronic myelogenous leukemia: the long road to imatinib. J Clin Invest. 117, 2036-2043.
40. Jahnke, W., and Erlanson, D. A. (eds.) (2006). Fragment-Based Approaches in Drug Discovery, Vol. 34. Weinheim, Germany: Wiley-VCH.
41. Jencks, W. P. (1981). On the attribution and additivity of binding energies. Proc Natl Acad Sci USA. 78, 4046-4050.
42. Kane, R. C., Farrell, A. T., Saber, H., et al. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 12, 7271-7278.
43. Karaman, M. W., Herrgard, S., Treiber, D. K., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26, 127-132.
44. Keen, N., and Taylor, S. (2004). Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer. 4, 927-936.
45. Kuntz, I. D., Chen, K., Sharp, K. A., and Kollman, P. A. (1999). The maximal affinity of ligands. Proc Natl Acad Sci USA. 96, 9997-10002.
46. Lange, G., Lesuisse, D., Deprez, P., et al. (2003). Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J Med Chem. 46, 5184-5195.
47. Lesuisse, D., Lange, G., Deprez, P., et al. (2002). SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J Med Chem. 45, 2379-2387.
48. Liao, J. J. (2007). Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem. 50, 409-424.
49. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 23, 3-25.
50. Lowinger, T. B., Riedl, B., Dumas, J., and Smith, R. A. (2002). Design and discovery of small molecules targeting raf-1 kinase. Curr Pharm Des. 8, 2269-2278.
51. Maly, D. J., Choong, I. C., and Ellman, J. A. (2000). Combinatorial target-guided ligand assembly: identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci USA. 97, 2419-2424.
52. McGovern, S. L., and Shoichet, B. K. (2003). Kinase inhibitors: not just for kinases anymore. J Med Chem. 46, 1478-1483.
53. McGovern, S. L., Caselli, E., Grigorieff, N., and Shoichet, B. K. (2002). A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem. 45, 1712-1722.
54. McGovern, S. L., Helfand, B. T., Feng, B., and Shoichet, B. K. (2003). A specific mechanism of nonspecific inhibition. J Med Chem. 46, 4265-4272.
55. Meyer, S. C., Shomin, C. D., Gaj, T., and Ghosh, I. (2007). Tethering small molecules to a phage display library: discovery of a selective bivalent inhibitor of protein kinase A. J Am Chem Soc. 129, 13812-13813.
56. Mora, A., Komander, D., van Aalten, D. M., and Alessi, D. R. (2004). PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 15, 161-170.
57. Murray, C. W., and Verdonk, M. L. (2002). The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J Comput Aided Mol Des. 16, 741-753.
58. Nagar, B., Bornmann, W. G., Pellicena, P., et al. (2002). Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62, 4236-4243.
59. Ohren, J. F., Chen, H., Pavlovsky, A., et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 11, 1192-1197.
60. Pargellis, C., Tong, L., Churchill, L., et al. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol. 9, 268-272.
61. Ramstrom, O., and Lehn, J. M. (2002). Drug discovery by dynamic combinatorial libraries. Nat Rev Drug Discov. 1, 26-32.
62. Rees, D. C., Congreve, M., Murray, C. W., and Carr, R. (2004). Fragment-based lead discovery. Nat Rev Drug Discov. 3, 660-672.
63. Reynolds, C. H., Tounge, B. A., and Bembenek, S. D. (2008). Ligand binding effi-ciency: trends, physical basis, and implications. J Med Chem. 51, 2432-2438.
64. Ricouart, A., Gesquiere, J. C., Tartar, A., and Sergheraert, C. (1991). Design of potent protein kinase inhibitors using the bisubstrate approach. J Med Chem. 34, 73-78.
65. Rishton, G. M. (2003). Nonleadlikeness and leadlikeness in biochemical screening. Drug Discov Today. 8, 86-96.
66. Rowan, S. J., Cantrill, S. J., Cousins, G. R. L., Sanders, J. K. M., and Stoddart, J. F. (2002). Dynamic covalent chemistry. Angew Chem Int Ed. 41, 898-952.
67. Ryan, A. J., Gray, N. M., Lowe, P. N., and Chung, C. W. (2003). Effect of detergent on " promiscuous " inhibitors. J Med Chem. 46, 3448-3451.
68. Saxty, G., Woodhead, S. J., Berdini, V., et al. (2007). Identification of inhibitors of protein kinase B using fragment-based lead discovery. J Med Chem. 50, 2293-2296.
69. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289, 1938-1942.
70. Schneider, T. L., Mathew, R. S., Rice, K. P., Tamaki, K., Wood, J. L., and Schepartz, A. (2005). Increasing the kinase specificity of k252a by protein surface recognition. Org Lett. 7, 1695-1698.
71. Schreiber, S., Feagan, B., D ' Haens, G., et al. (2006). Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn ' s disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 4, 325-334.
72. Sem, D. S. (2006). NMR-guided fragment assembly. In: W. Jahnke and D. A. Erlanson (eds.). Fragment-Based Approaches in Drug Discovery, Vol. 34. Weinheim, Germany: Wiley-VCH, pp. 149-180.
73. Shen, K., and Cole, P. A. (2003). Conversion of a tyrosine kinase protein substrate to a high affinity ligand by ATP linkage. J Am Chem Soc. 125, 16172-16173.
74. Shuker, S. B., Hajduk, P. J., Meadows, R. P., and Fesik, S. W. (1996). Discovering high-affinity ligands for proteins: SAR by NMR. Science. 274, 1531-1534.
75. Teague, S. J., Davis, A. M., Leeson, P. D., and Oprea, T. (1999). The design of leadlike combinatorial libraries. Angew Chem Int Ed Engl. 38, 3743-3748.
76. Tsai, J., Lee, J. T., Wang, W., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 105, 3041-3046.
77. Vazquez, J., De, S. K., Chen, L. H., et al. (2008). Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem. 51, 3460-3465.
78. Wang, J. Y., Wilcoxen, K. M., Nomoto, K., and Wu, S. (2007). Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem. 7, 1364-1378.
79. Warner, S. L., Bashyam, S., Vankayalapati, H., et al. (2006). Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment -based approach. Mol Cancer Ther. 5, 1764-1773.
80. Wyatt, P. G., Woodhead, A. J., Berdini, V., et al. (2008). Identification of N-(4 -piperidinyl)-4-(2, 6-dichlorobenzoylamino)-1 H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem. 51, 4986-4999.
81. Zhao, H., Serby, M. D., Xin, Z., et al. (2006). Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH(2)-terminal kinase inhibitors. J Med Chem. 49, 4455-4458.